Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Tolerability of Dapirolizumab Pegol in Systemic Lupus Erythematosus
NCT04976322Phase 3Enrolling by invitation
- Sponsor
- UCB
- Start
- Jul 2021
- Primary completion
- Aug 2030
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 24
01
Overview
A Phase 3 trial of dapirolizumab pegol in systemic lupus erythematosus (SLE), sponsored by UCB. Started Jul 2021; status: enrolling by invitation.
02
Drugs
dapirolizumab pegol
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04976322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04976322.